 |
인쇄하기
취소
|
Counterattacks of the 2nd line drug in Rheumatoid Arthritis drugs… all efforts on market penetration
Reimbursement extended of Orencia and Acktemla as primary drug … competing with Humira.
(Yakup Shinmoon)
The 2nd line drug of rheumatoid arthritis extended insurance reimbursement coverage as the 1st drug. Therefore, the first and second line drugs are going to compete.
According to pharmaceutical companies, inhibitor against TNF-a, BMS’s ‘Orencia’ and JW choong-wae’s ‘Aktemra’ have expa...
(Yakup Shinmoon)
The 2nd line drug of rheumatoid arthritis extended insurance reimbursement coverage as the 1st drug. Therefore, the first and second line drugs are going to compete.
According to pharmaceutical companies, inhibitor against TNF-a, BMS’s ‘Orencia’ and JW choong-wae’s ‘Aktemra’ have expa...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.